Ipsen's Tazverik Exit and Rare Disease Bets Signal Pipeline Pivot

Ipsen's voluntary withdrawal of Tazverik (tazemetostat) from all indications and all markets, effective 9 March 2026, following emerging safety data from the ongoing Phase Ib/III SYMPHONY-1 trial in follicular lymphoma, places the company's pharmacovigilance infrastructure and post-approval safety monitoring protocols under scrutiny. For QA directors and regulatory affairs leads, the decision underscores the operational weight of maintaining robust signal-detection systems across late-stage oncology programs, particularly where conditional or accelerated approvals carry ongoing confirmatory trial obligations.

Against that backdrop, Ipsen reported Q1 2026 total sales of EUR 1,074.9 million, representing growth of 22.6% at constant exchange rates (CER) and 17.0% as reported. The rare disease segment led growth at 109.1% as reported (125.4% at CER), driven by the rare liver disease franchise anchored by Iqirvo and Bylvay. Oncology contributed EUR 707.5 million (+13.0% CER) and neuroscience EUR 220.3 million (+18.5% CER). Portfolio sales excluding Somatuline grew 27.5% at CER, a figure relevant to manufacturing planners managing capacity reallocation as the Somatuline franchise faces generic lanreotide pressure.

Three pivotal Phase III readouts are expected in H2 2026: the ELSPIRE trial for Iqirvo in primary biliary cholangitis, the BOLD trial for Bylvay in biliary atresia, and the BEOND trials for Dysport in chronic and episodic migraine. Each readout carries distinct manufacturing preparedness implications -- from sterility assurance requirements for biologics to fill-finish scalability for a potential migraine indication expansion. On 22 April 2026, Ipsen also received conditional marketing authorization from the European Commission for Ojemda (tovorafenib) in pediatric low-grade glioma, based on pivotal Phase II FIREFLY-1 data, adding a pediatric oncology asset requiring age-appropriate formulation and GMP-compliant manufacturing scale-up.

Ipsen confirmed full-year 2026 guidance of total sales growth greater than 13.0% at CER and a core operating margin greater than 35.0% of total sales. The company also entered a global collaboration and exclusive option agreement with Origami Therapeutics on 30 January 2026, targeting a protein-degrader program in rare neurodegenerative diseases. Pharma Now reporting is based on Ipsen's press release published via GlobeNewswire on 23 April 2026.